A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

British Journal of Haematology

Volumn 103, Issue 1, 1998, Pages 100-109

  Wheatley, K ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

AML; Anthracycline; Idarubicin; Induction; Overview

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

ACUTE DISEASE; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0005040904     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00948.x     Document Type: Article

References (21)

1. Antiplatelet Trialists' Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. British Medical Journal, 296, 320-331.
2. Berman, E. & McBride, M. (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood, 79, 3267-3273.
3. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Gabrilove, J., Reich, L., Mayer, K., Keefe, D., Trainor, K., Schluger, A., Penenberg, D., Raymond, V., O'Reilly, R., Jhanwar, S., Young, C. & Clarkson, B. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed AML. Blood, 77, 1666-1674.
4. Bezwoda, W.R. & Dansey, R.D. (1990) Idarubicin plus cytarabine versus doxorubicin plus cytarabine in induction therapy for acute non-lymphoid leukemia: a randomized trial. Leukemia and Lymphoma, 1, 221-225.
5. Büchner, T., Hiddemann, W., Wörmann, B., Löffler, H., Maschmeyer, G., Hossfeld, D., Ludwig, W-D., Nowrousian, M., Aul, C., Schaefer, U.W., Sauerland, C. & Heinecke, A. (1992) Long-term effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia, 6, (Suppl. 2), 68-71.
6. Carella, A., Berman, E., Maraone, M.P. & Ganzina, F. (1990) Idarubicin in the treatment of acute leukemias: an overview of preclinical and clinical studies. Haematologica, 75, 159-169.
7. Clarke, M.J. & Stewart, L.A. (1994) Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses? British Medical Journal, 309, 1007-1010.
8. Early Breast Cancer Trialists' Collaborative Group (1990) Treatment of Early Breast Cancer, Vol. 1, Worldwide Evidence 1985-1990. Oxford University Press.
9. Eridani, S., Singh, A.K., Slater, N.G.P., Pearson, T.C., Phaure, T.A.J., Semple, M.J., Erskine, J.G., Toolis, F. & Birch, A.D.J. (1989) A phase II study of idarubicin versus daunorubicin in the treatment of acute non-lymphocytic leukaemia. Cancer Journal, 2, 296-299.
10. Gonzalez-Llaven, J., Rubio-Borja, M.E. & Ovilla Martinez, R. (1991) Efficacy of idarubicin plus Ara-C in induction remission of de novo adult acute nonlymphoblastic leukemia. Haematologica, 76, (Suppl. 4), 128.
11. Harousseau, J.L., Pignon, B., Witz, F., Polin, V., Tellier, Z., Hurteloup, P. & Cahn, J.Y. (1996) Treatment of acute myeloblastic leukaemia in adults: the GOELAM experience. Haematology and Cell Therapy, 38, 381-391.
12. Mandelli, F., Petti, M.C., Ardia, A., Di-Pietro, N., Di-Raimondo, F., Ganzina, F., Falconi, E., Geraci, E., Ladogana, S., Latagliata, R., Malleo, C., Nobile, F., Petti, N., Rotoli, B., Specchia, G., Tabilio, A. & Resegotti, L. (1991) A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of ANLL: a multicentric study from the Italian cooperative group GIMEMA. European Journal of Cancer, 27, 750-755.
13. Mayer, R.J., Davis, R.B. & Schiffer, C.A. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903.
14. Peto, R. (1987) Why do we need systematic overviews of randomized trials? Statistics in Medicine, 6, 233-240.
15. Peto, R., Collins, R., Gray, R. & Parish, S. (1996) Large-scale randomized evidence: large, simple trials and overviews of trials. Oxford Textbook of Medicine, 3rd edn (ed. by D. J. Weatherall, D. A. Warrell and J. G. G. Ledingham), Vol. 1. pp. 21-32. Oxford University Press.
16. Rieffers, J., Huguet, F., Stoppa, A-M., Molina, L., Marit, G., Attal, M., Gastaut, J.A., Michallet, M., Lepeu, G., Braustet, A., Pris, J., Maraninchi, D., Hollard, D., Fabères, C., Mercier, M., Hurteloup, P., Danel, P., Tellier, Z. & Berthaud, P. (1996) A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia, 10, 389-395.
17. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A. & Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86, 457-462.
18. Stewart, L.A. & Parmar, M.K.B. (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet, 341, 418-422.
19. Vogler, W.R., Velez-Garcia, E., Weiner, R.S., Flaum, M.A., Bartolucci, A.A., Omura, G.A., Gerber, M.C. & Banks, P.L.C. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. Journal of Clinical Oncology 10, 1103-1111.
20. Wiernik, P.H., Banks, P.L.C., Case, D.C., Arlin, Z.A., Periman, P.O., Todd, M.B., Ritch, P.S., Enck, R.E. & Weitberg, A.B. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79, 313-319.
21. Yates, J., Glidewell, O., Wiernik, P., Cooper, M.R., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchison, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., James, G.W., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland, J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood, 60, 454-462.